We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Progressing Well With its Coronavirus Program
Read MoreHide Full Article
Pfizer (PFE - Free Report) is collaborating with other pharma/biotech companies as well as government agencies and academic institutions to develop different types of therapies against coronavirus infection, COVID-19.
The company is developing an mRNA-based vaccine, antiviral compounds and a JAK inhibitor to fight COVID-19.
Last month, the company signed a deal with BioNTech (BNTX - Free Report) to jointly develop the latter’s mRNA-based vaccine candidate, BNT162, to prevent the COVID-19 infection. The collaboration aims to accelerate the global development of BNT162, leveraging the expertise and resources of both companies. BNT162 is expected to enter clinical testing by the end of this month. Both companies planned to initially develop the vaccine in the United States and Europe, and scale-up manufacturing capacity to support global supply. Per the deal, BioNTech will receive an upfront payment of $185 million, including approximately $113 million in equity investment. BioNTech is also eligible to receive future milestone payments of up to $563 million.
Pfizer said they have potential to supply millions of vaccine doses by the end of 2020 if they receive the necessary regulatory approvals. Thereafter, they can rapidly scale up capacity to produce hundreds of millions of doses in 2021.
Pfizer is also screening antiviral compounds and has confirmed a lead compound based on the results of initial screening assays. The company plans to start a potential clinical study of the lead molecule in the third quarter of 2020. It is also evaluating azithromycin for its antiviral properties.
Moreover, an independent, investigator-initiated phase II study is being planned to evaluate Pfizer’s JAK inhibitor, tofacitinib, in patients with SARS-CoV-2 interstitial pneumonia in Italy later this week. The company is in discussions with other institutions about additional studies involving tofacitinib and potentially other immune modulators in its portfolio to mitigate systemic and alveolar inflammation in patients with COVID-19-related pneumonia.
Pfizer’s shares have lost 9.7% so far this year compared with the industry’s decline of 6.6%.
Please note that several pharma/biotech companies are engaged in developing vaccines or treatments for the coronavirus infection. Moderna (MRNA - Free Report) is another company developing an mRNA-based vaccine for COVID-19. The candidate is in clinical-stage development.Translate Bio is also planning to co-develop an mRNA-based vaccine in collaboration with Sanofi (SNY - Free Report) . Pharma giant, J&J has announced plans to initiate a clinical study to evaluate its potential coronavirus vaccine candidate in September.
Apart from vaccines, a few other companies are developing drugs or testing their marketed drugs in studies to treat COVID-19. These include Gilead’s antiviral candidate, remdesivir; Roche’s rheumatoid arthritis (“RA”) drug, Actemra; and Regeneron/Sanofi’s RA drug, Kevzara. While Actemra is being evaluated for severe COVID-19 pneumonia, Kevzara is being evaluated in patients hospitalized with severe infection due to COVID-19.
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.5% per year.
These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
Pfizer (PFE) Progressing Well With its Coronavirus Program
Pfizer (PFE - Free Report) is collaborating with other pharma/biotech companies as well as government agencies and academic institutions to develop different types of therapies against coronavirus infection, COVID-19.
The company is developing an mRNA-based vaccine, antiviral compounds and a JAK inhibitor to fight COVID-19.
Last month, the company signed a deal with BioNTech (BNTX - Free Report) to jointly develop the latter’s mRNA-based vaccine candidate, BNT162, to prevent the COVID-19 infection. The collaboration aims to accelerate the global development of BNT162, leveraging the expertise and resources of both companies. BNT162 is expected to enter clinical testing by the end of this month. Both companies planned to initially develop the vaccine in the United States and Europe, and scale-up manufacturing capacity to support global supply. Per the deal, BioNTech will receive an upfront payment of $185 million, including approximately $113 million in equity investment. BioNTech is also eligible to receive future milestone payments of up to $563 million.
Pfizer said they have potential to supply millions of vaccine doses by the end of 2020 if they receive the necessary regulatory approvals. Thereafter, they can rapidly scale up capacity to produce hundreds of millions of doses in 2021.
Pfizer is also screening antiviral compounds and has confirmed a lead compound based on the results of initial screening assays. The company plans to start a potential clinical study of the lead molecule in the third quarter of 2020. It is also evaluating azithromycin for its antiviral properties.
Moreover, an independent, investigator-initiated phase II study is being planned to evaluate Pfizer’s JAK inhibitor, tofacitinib, in patients with SARS-CoV-2 interstitial pneumonia in Italy later this week. The company is in discussions with other institutions about additional studies involving tofacitinib and potentially other immune modulators in its portfolio to mitigate systemic and alveolar inflammation in patients with COVID-19-related pneumonia.
Pfizer’s shares have lost 9.7% so far this year compared with the industry’s decline of 6.6%.
Please note that several pharma/biotech companies are engaged in developing vaccines or treatments for the coronavirus infection. Moderna (MRNA - Free Report) is another company developing an mRNA-based vaccine for COVID-19. The candidate is in clinical-stage development.Translate Bio is also planning to co-develop an mRNA-based vaccine in collaboration with Sanofi (SNY - Free Report) . Pharma giant, J&J has announced plans to initiate a clinical study to evaluate its potential coronavirus vaccine candidate in September.
Apart from vaccines, a few other companies are developing drugs or testing their marketed drugs in studies to treat COVID-19. These include Gilead’s antiviral candidate, remdesivir; Roche’s rheumatoid arthritis (“RA”) drug, Actemra; and Regeneron/Sanofi’s RA drug, Kevzara. While Actemra is being evaluated for severe COVID-19 pneumonia, Kevzara is being evaluated in patients hospitalized with severe infection due to COVID-19.
Pfizer Inc. Price
Pfizer Inc. price | Pfizer Inc. Quote
Zacks Rank
Pfizer currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.5% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>